NCT06504043View on ClinicalTrials.gov

A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

January 8, 2025

Study Completion Date

March 31, 2025

Conditions
HypercholesterolemiaHealthy VolunteersLDL-Cholesterol
Interventions
DRUG

HST101

HST101 is a novel anti-PCSK9 fusion protein

Trial Locations (1)

610044

West China Hospital of Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

Hasten Biopharmaceutical Co., Ltd.

INDUSTRY